OncoMatch/Clinical Trials/NCT06673693
Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma
Is NCT06673693 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Tislelizumab for head and neck squamous cell carcinoma (hnscc).
Treatment: Tislelizumab — Exploring the efficacy and safety of Tislelizumab combined with stereotactic body radiation therapy (SBRT) as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (HNSCC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IVA, IVB
Demographics
Prior therapy
Cannot have received: surgery
Exception: diagnostic biopsies of primary and regional lymph nodes
Patients previously treated with head and neck surgery were excluded from diagnostic biopsies of primary and regional lymph nodes
Cannot have received: chemotherapy
Previous chemotherapy for any reason
Cannot have received: radiation therapy
radiotherapy in the head and neck area
Cannot have received: molecular targeted drug therapy
molecular targeted drug therapy
Cannot have received: anti-PD-1 therapy
anti-PD-1, anti-PD-L1, anti-PD-L2 and other drugs or drugs acting on another irritating or co-inhibitory T cell receptor (such as CTLA-4, OX 40, CD137) treatment
Cannot have received: cell biotherapy
cell biotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06673693 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage III or IVA or IVB is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages